DexCom Inc. (DXCM) Shares Decline by -1.82% to Close at $114.61

As of close of business last night, DexCom Inc.’s stock clocked out at $114.61, down -1.82% from its previous closing price of $116.73. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 2458004 shares were traded. DXCM stock price reached its highest trading level at $116.66 during the session, while it also had its lowest trading level at $112.27.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



To gain a deeper understanding of DXCM’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 108.53. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.56.

Upgrades & Downgrades

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 23 when Pacelli Steven Robert sold 412 shares for $118.65 per share. The transaction valued at 48,884 led to the insider holds 132,274 shares of the business.

Sylvain Jereme M sold 2,400 shares of DXCM for $282,192 on May 22. The EVP Chief Financial Officer now owns 74,711 shares after completing the transaction at $117.58 per share. On May 09, another insider, Stern Sadie, who serves as the EVP Chief Human Resources Offi of the company, sold 393 shares for $120.19 each. As a result, the insider received 47,235 and left with 82,859 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 47.04B and an Enterprise Value of 46.72B. As of this moment, DexCom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 166.10, and their Forward P/E ratio for the next fiscal year is 76.56. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 8.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.94 while its Price-to-Book (P/B) ratio in mrq is 19.86. Its current Enterprise Value per Revenue stands at 16.06 whereas that against EBITDA is 82.65.

Stock Price History:

Over the past 52 weeks, DXCM has reached a high of $126.44, while it has fallen to a 52-week low of $66.89. The 50-Day Moving Average of the stock is 117.90, while the 200-Day Moving Average is calculated to be 107.79.

Shares Statistics:

It appears that DXCM traded 2.15M shares on average per day over the past three months and 1.85M shares per day over the past ten days. A total of 386.70M shares are outstanding, with a floating share count of 384.65M. Insiders hold about 0.10% of the company’s shares, while institutions hold 98.80% stake in the company. Shares short for DXCM as of May 14, 2023 were 14.46M with a Short Ratio of 14.46M, compared to 12.08M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.73% and a Short% of Float of 4.22%.

Earnings Estimates

As of right now, 19 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.23 for the current quarter, with a high estimate of $0.3 and a low estimate of $0.16, while EPS last year was $0.17. The consensus estimate for the next quarter is $0.32, with high estimates of $0.36 and low estimates of $0.28.

Analysts are recommending an EPS of between $1.23 and $0.95 for the fiscal current year, implying an average EPS of $1.09. EPS for the following year is $1.5, with 20 analysts recommending between $1.73 and $1.14.

Revenue Estimates

In the current quarter, 17 analysts expect revenue to total $841.57M. It ranges from a high estimate of $860M to a low estimate of $828.57M. As of the current estimate, DexCom Inc.’s year-ago sales were $696.2M, an estimated increase of 20.90% from the year-ago figure. For the next quarter, 17 analysts are estimating revenue of $928.85M, an increase of 23.70% over than the figure of $20.90% in the same quarter last year. There is a high estimate of $961M for the next quarter, whereas the lowest estimate is $912.38M.

A total of 21 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $3.55B, while the lowest revenue estimate was $3.46B, resulting in an average revenue estimate of $3.5B. In the same quarter a year ago, actual revenue was $2.91B, up 20.30% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $4.22B in the next fiscal year. The high estimate is $4.39B and the low estimate is $4.09B. The average revenue growth estimate for next year is up 20.50% from the average revenue estimate for this year.